The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Anti-Parkinson Drugs Market In 2026 And 2030?
The anti-parkinson drugs market size has demonstrated consistent expansion in recent years. It is projected to grow from $10.96 billion in 2025 to $11.46 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.6%. The historical growth can be attributed to factors such as an aging population growth, increased parkinson’s disease diagnosis, the long-standing use of levodopa, improved neurological care, and the needs for chronic disease management.
The anti-parkinson drugs market is projected to experience substantial expansion over the forthcoming years. It is anticipated to reach a valuation of $14.28 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. This projected increase during the forecast period stems from factors such as a rise in neurodegenerative disorders, advancements in neuroprotective drugs, the spread of transdermal therapies, improved access to healthcare, and an emphasis on enhancing the quality of life. Key developments expected during this period involve an escalating demand for dopaminergic therapies, a greater adoption of extended-release formulations, a heightened focus on managing symptoms, the proliferation of combination drug therapies, and enhancements in drug delivery technologies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp
What Significant Factors Are Influencing The Anti-Parkinson Drugs Market Expansion?
The increasing occurrence of mental health disorders is projected to boost the growth of the mental wellness market moving forward. Mental health disorders are characterized as a clinically significant impairment in an individual’s cognition, emotional regulation, or behavior. The rising prevalence of mental disorders is attributed to heightened exposure to chronic stress and adverse life experiences that can overwhelm personal coping mechanisms and trigger psychological dysfunction. This growing incidence of mental disorders expands the anti-Parkinson drugs market, as these drugs aid in minimizing and curing mental disorders. For instance, in October 2025, according to the Institute for Health Metrics and Evaluation, a US-based health research organization, 15% of the world’s population experienced mental disorders in 2023 and 17% of the total years lived with disability globally were attributed to mental disorders in the same year. Therefore, the high prevalence of mental disorder is driving the growth of the anti-Parkinson drugs market.
Which Segments Define The Anti-Parkinson Drugs Market Segment Structure?
The anti-parkinson drugs market covered in this report is segmented –
1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
Subsegments:
1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa
2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine
3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone
5) By Anticholinergics: Benztropine, Trihexyphenidyl
6) By Other Drugs: Amantadine, Apomorphine
What Trends Are Shaping The Future Of The Anti-Parkinson Drugs Market?
Major companies in the anti-Parkinson drugs market are concentrating on developing advanced therapeutic solutions for conditions like motor fluctuations and dyskinesia to improve symptom management and reduce side effects. Motor fluctuations and dyskinesia frequently complicate the treatment of Parkinson’s disease, adversely affecting patient well-being. For instance, in January 2024, AbbVie Inc., a US-based pharmaceutical company, introduced PRODUODOPA. PRODUODOPA (foslevodopa/foscarbidopa) is the inaugural subcutaneous 24-hour infusion therapy for advanced Parkinson’s disease, specifically addressing severe motor fluctuations and dyskinesia when other treatments prove ineffective. It provides a continuous delivery of levodopa, potentially increasing ‘on’ time and enhancing symptom control.
Who Are The Established Players Within The Anti-Parkinson Drugs Market?
Major companies operating in the anti-parkinson drugs market are GlaxoSmithKline plc, Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.
Get The Full Anti-Parkinson Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report
Which Region Is The Largest In The Anti-Parkinson Drugs Market?
North America was the largest region in the anti-Parkinson drugs market in 2025. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Anti-Parkinson Drugs Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report
Browse Through More Reports Similar to the Global Anti-Parkinson Drugs Market 2026, By The Business Research Company
Anti Parkinson Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report
Neurological Disorder Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report
Anticholinergic Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model